J. Isenberg

Financing REDD in developing countries: a supply and demand analysis.

Reducing emissions from deforestation and forest degradation (REDD) in developing countries has been at the centre of negotiations on a renewed international climate regime. Developing countries have made it clear that their ability to engage in REDD activities would depend on obtaining sufficient and stable funding. Two alternative REDD financing options are examined to find possible ways forward: financing through a future compliance market and financing through a non-offset fund. First, global demand for hypothetical REDD credits is estimated. The demand for REDD credits would be highest with a base year of 1990, using gross—net accounting. The key factors determining demand in this scenario are the emission reduction targets and the allowable cap. A proportion of emission reduction targets available for offsets lower than 15% would fail to generate a sufficient demand for REDD. Also examined is the option of financing REDD through a fund. Indirectly linking the replenishment of a REDD fund to the market is a promising mechanism, but its feasibility depends on political will. The example of overseas development assistance for global health indicates the conditions for possible REDD financing. The best financial approach for REDD would be a flexible REDD mechanism with two tracks: a market track serving as a mitigation option for developed countries, and a fund track serving as a mitigation option for developing countries.

Imatinib Mesylate Alters the Expression of Genes Related to Disease Progression in an Animal Model of Uveal Melanoma

Imatinib mesylate (IM) is a compound that inhibits both BCR-ABL tyrosine kinase and c-kit receptors. Tyrosine kinases are important in cellular signaling and mediate major cellular processes such as proliferation, differentiation, apoptosis, attachment, and migration. Twenty-six albino rabbits were injected with 1 × 106 human uveal melanoma (UM) cells (92.1) into the suprachoroidal space. Animals were immunosuppressed (cyclosporin A) over the course of the 12-week experiment and divided into two groups (n = 13). The experimental group received IM once daily by gavage while the control group received a placebo. One animal per group was sacrificed every week after the 2nd week. Upon necropsy, organs were harvested for histopathological examination. Cells from the primary tumors were recultured and tested in proliferation and invasion assays. A PCR array was used to investigate the differences in expression of 84 genes related to tumor metastasis. In the treated group, 4 rabbits developed intraocular tumors, with an average largest tumor dimension (LTD) of 2.5 mm and 5 animals reported metastatic disease. Whereas 6 rabbits in the control group developed intraocular tumors, with an average LTD of 5.8 mm and 6 animals reported metastatic disease. The recultured cells from the treated group demonstrated lower proliferation rates and were less invasive (p < 0.001 The PCR array showed differences in expression of genes related to metastasis. Notably, there was 290-fold increase in SERPINB5, a tumor suppressor gene, and a 10-fold higher expression of KISS1, a metastasis suppressor gene, in the treated group. Proangiogenic genes such as VEGFA, PDGFA and PDGFB were downregulated in the treated group. To the best of our knowledge, this is the first report detailing the altered expression of specific genes in UM cells after treatment with IM.

Peptidyl-prolyl cis-trans isomerase A – A novel biomarker of multi-episodic (recurrent) ocular toxoplasmosis

&NA; Ocular toxoplasmosis (OT) is the most common etiology of posterior uveitis. The high incidence of macular scarring associated with OT is a leading cause of visual morbidity. Serum biomarkers of the disease would aid in its diagnosis. This study sought, for the first time, to elucidate serum biomarkers for OT by mass spectrometry. Blood samples were collected from four groups of nine patients each; toxoplasmosis IgG‐with no history of uveitis, non‐toxoplasmosis uveitis, first episode OT, and symptomatic recurrent OT. Serum was isolated and subjected to proteomics analysis using 2‐dimensional gel electrophoresis (2D‐GE) and surface‐enhanced laser desorption ionization mass spectrometry (SELDI‐MS). Selected proteins were further separated by SDS‐PAGE and sequenced using tandem MS. Results were cross‐validated with a T. gondii outbreak biomarker database that occurred in Brazil. Fifty markers of OT and 46 markers of recurrent disease were discovered by SELDI‐MS of which 30 and 15, respectively, were cross‐validated. 2D‐GE analysis yielded 57 bands, selected based on the intensity of the bands, leading to the identification of 20 proteins. Eleven of those identified candidates were also found by SELDI‐MS. Four candidates were chosen for immunoblotting. One serum protein, peptidyl‐prolyl cis‐trans isomerase A (PPIA), was confirmed as a biomarker of multi‐episodic OT by immunoblotting in patients. PPIA can identify the patient with active recurrent OT from acute OT, other forms of uveitis and other parasitic infections. A validated PPIA assay may have a role in the diagnosis of the atypical OT patient before more invasive anterior chamber or vitreous tap is performed for PCR analysis or for Goldmann‐Witner coefficient calculations. Base‐line PPIA levels need to be studied to understand its possible use when deciding for prophylactic antibiotic use in the immunosuppressed sero‐positive patient.

Metastatic choroidal melanoma to the contralateral eye: a rare case

Uveal melanoma is the most common adult primary intraocular cancer. Although liver metastasis is common to the natural history of the disease, metastasis to the fellow eye is extremely rare. Here we report the case of a 59-year-old man with choroidal melanoma in his right eye who underwent enucleation at a different center. The patient was referred to our service 21 months postoperatively, complaining of decreased vision. He was found to have a new pigmented choroidal tumor in his left eye associated with liver disease. Ocular ultrasonography and liver biopsy with histopathological and immunohistochemical analysis were performed and confirmed the diagnosis. Few similar cases have been described in the literature. The differential diagnosis included primary bilateral choroidal melanoma and metastatic choroidal tumor from a primary skin melanoma.